Enhabit Inc (EHAB)’s Market Momentum: Closing Strong at 8.64, Up 3.60

Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.

As of close of business last night, Enhabit Inc’s stock clocked out at $8.64, up 3.60% from its previous closing price of $8.34. In other words, the price has increased by $3.60 from its previous closing price. On the day, 1.11 million shares were traded. EHAB stock price reached its highest trading level at $8.9 during the session, while it also had its lowest trading level at $8.57.

Ratios:

To gain a deeper understanding of EHAB’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 11.00 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 15.37. For the most recent quarter (mrq), Quick Ratio is recorded 1.50 and its Current Ratio is at 1.50. In the meantime, Its Debt-to-Equity ratio is 0.90 whereas as Long-Term Debt/Eq ratio is at 0.85.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Jefferies on May 09, 2024, Downgraded its rating to Hold and sets its target price to $8.75 from $14 previously.

On March 07, 2024, UBS Upgraded its rating to Neutral which previously was Sell but kept the price unchanged to $9.50.

On December 12, 2023, TD Cowen started tracking the stock assigning a Market Perform rating and target price of $12.TD Cowen initiated its Market Perform rating on December 12, 2023, with a $12 target price.

Insider Transactions:

Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 10 ’24 when Bolton Jeffrey bought 10,000 shares for $8.24 per share. The transaction valued at 82,400 led to the insider holds 42,299 shares of the business.

Langham Ronald Leroy JR sold 634 shares of EHAB for $5,586 on Mar 01 ’24. The EVP Clinical Excel. & Strategy now owns 57,164 shares after completing the transaction at $8.81 per share. On May 26 ’23, another insider, Bolton Jeffrey, who serves as the Director of the company, bought 2,000 shares for $11.61 each. As a result, the insider paid 23,220 and bolstered with 19,597 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EHAB now has a Market Capitalization of 432355136 and an Enterprise Value of 1035042816. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.42 while its Price-to-Book (P/B) ratio in mrq is 0.65. Its current Enterprise Value per Revenue stands at 0.992 whereas that against EBITDA is 15.266.

Stock Price History:

Over the past 52 weeks, EHAB has reached a high of $14.59, while it has fallen to a 52-week low of $7.12. The 50-Day Moving Average of the stock is -16.16%, while the 200-Day Moving Average is calculated to be -17.27%.

Shares Statistics:

It appears that EHAB traded 621.68K shares on average per day over the past three months and 816410 shares per day over the past ten days. A total of 50.05M shares are outstanding, with a floating share count of 44.02M. Insiders hold about 12.24% of the company’s shares, while institutions hold 101.68% stake in the company. Shares short for EHAB as of 1714435200 were 3059902 with a Short Ratio of 4.92, compared to 1711584000 on 3532199. Therefore, it implies a Short% of Shares Outstanding of 3059902 and a Short% of Float of 10.13.

Most Popular

[the_ad id="945"]